Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2008
Event: Entry into a Material Definitive Agreement.
Key Financial Metrics
This filing is a current report regarding a corporate agreement and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreement Details
On April 10, 2008, Biochrom Limited (a wholly owned subsidiary of Harvard Bioscience, Inc.) entered into a distribution agreement with General Electric Company (acting through GE Healthcare Bio-Sciences). Key terms include:
- Role: GE Healthcare will serve as the exclusive, worldwide distributor (except Canada) for a significant portion of Biochrom's spectrophotometer and DNA/RNA calculator product lines.
- Exclusive Access: GE Healthcare has exclusive worldwide access (including Canada) to the recently launched microliter spectrophotometer.
- Term: The agreement expires on December 31, 2012.
- Extension: GE Healthcare may extend the agreement for additional one-year periods.
- Termination: Either party may terminate with one year's advance written notice after March 27, 2009. Termination with 60-day notice is permitted upon breach of certain terms.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary beyond the description of the agreement. The primary risk noted is the potential for termination by either party after March 27, 2009, or upon breach of terms.
Investor Verification Checklist
- Verify the specific product lines covered under the "significant portion" of the spectrophotometer and DNA/RNA calculator categories.
- Confirm the revenue contribution of the microliter spectrophotometer to assess the impact of GE Healthcare's exclusive worldwide access.
- Review the termination clauses to understand the stability of the distribution channel post-March 2009.
- Check subsequent filings for any financial impact or revenue recognition related to this agreement.